When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb (BMY 1.61%). The stock has been pummeled in 2025, plunging 23% year to date (at the time of this writing) amid broader market turbulence. This dramatic underperformance has created a rare buying opportunity for inve ...

Bristol-Myers Squibb Company or BMS ( BMY ) released its first quarter (Q1 2025) numbers yesterday, which aren't bad at all. But can they mark a break from the stock's sagging performance over the past month?Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants , tak ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of BMY either ...

Core Viewpoint - Bristol-Myers Squibb Company (BMY) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $1.80, exceeding expectations, despite a decline in overall revenues due to legacy portfolio sales [1][20]. Financial Performance - Adjusted EPS of $1.80 beat the Zacks Consensus Estimate of $1.51 and improved from an adjusted loss of $4.40 in the same quarter last year [1]. - Total revenues reached $11.2 billion, surpassing the Zacks Consensus Estimate of $10.7 billion, although down 6% from the previous year [1]. - U.S. revenues decreased 7% to $7.9 billion, while international revenues fell 2% year over year to $3.3 billion [3]. Growth Portfolio - Revenues from the Growth Portfolio amounted to $5.6 billion, reflecting a 16% increase year over year, driven by strong demand for key drugs [4]. - Notable sales growth was observed in Opdivo ($2.26 billion, up 9%), Reblozyl ($478 million, up 35%), and Breyanzi ($263 million, up 146%) [5][6][7]. - The Growth Portfolio's performance was bolstered by higher demand for Opdivo, Reblozyl, Breyanzi, Camzyos, Yervoy, and Opdualag [4]. Legacy Portfolio - Revenues from the Legacy Portfolio declined 20% to $5.64 billion, primarily due to generic competition affecting drugs like Revlimid and Pomalyst [10]. - Eliquis sales were $3.56 billion, down 4%, but exceeded expectations [10]. - Revlimid revenues plummeted 44% to $936 million, while Pomalyst and Sprycel also saw significant declines [12]. Cost Management - Gross margin decreased to 73.1% from 75.5% in the previous year, attributed to product mix changes [13]. - Adjusted R&D expenses decreased 5% to $2.2 billion, and adjusted marketing, selling, and administrative expenses fell 20% to $1.6 billion due to cost-cutting initiatives [13]. Guidance Update - The company raised its annual revenue guidance to $45.8-$46.8 billion, up from $45.5 billion, reflecting strong Growth Portfolio performance and favorable foreign exchange impacts [17]. - Adjusted EPS guidance was also increased to a range of $6.70-$7, compared to the previous guidance of $6.55-$6.85 [18]. Pipeline Developments - The FDA approved Opdivo plus Yervoy as a first-line treatment for unresectable or metastatic hepatocellular carcinoma [16]. - Updates on Camzyos and Cobenfy indicated some challenges in clinical trials, with the latter not meeting statistical significance for its primary endpoint [15].

Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elkins - CFO Adam Lenkowsky - CCO Samit Hirawat - CMO and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Geoff Meacham - Citi Evan Seigerman - BMO Capital Terence Flynn - Morgan Stanley Trung Huynh - UBS Courtney Breen - Berns ...

My last article about Bristol-Myers Squibb Company (NYSE: BMY ) was published in December 2024, and back then, I called the stock a "Buy" once again. In the meantime, the stock has declined about 14% compared to December 2024, and lost close to 25% in the lastMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraint ...

Financial Performance - Total revenues for Q1 2025 were $11,201 million, a decrease of 6% compared to $11,865 million in Q1 2024[133] - GAAP diluted earnings per share (EPS) for Q1 2025 was $1.20, a significant increase from a loss of $5.89 in Q1 2024[133] - Non-GAAP diluted EPS for Q1 2025 was $1.80, compared to a loss of $4.40 in Q1 2024[133] - U.S. revenues decreased by 7% to $7,873 million in Q1 2025, impacted by generic competition and redesign of the Medicare Part D program[145][147] - International revenues decreased by 3% to $3,110 million in Q1 2025, primarily due to foreign exchange impacts, but increased by 2% excluding these impacts[148] - Gross product sales for Q1 2025 were $19,874 million, a 3% increase from $19,295 million in Q1 2024[149] - Total revenues for the three months ended March 31, 2025, were $11,201 million, a decrease of 6% compared to $11,865 million in 2024[154] - The Growth Portfolio generated $5,563 million in revenue, reflecting a 16% increase from $4,792 million in the previous year[154] - The Legacy Portfolio saw a significant decline, with total revenues of $5,638 million, down 20% from $7,073 million[154] - Non-U.S. revenues for the total portfolio decreased by 2% to $3,328 million[154] Revenue Changes by Product - Eliquis revenue decreased by 4% to $3,565 million, with U.S. sales down 6% and Non-U.S. sales up 2%[154] - Revlimid revenue dropped 44% to $936 million, with U.S. sales also down 44%[154] - Pomalyst/Imnovid revenue decreased by 24% to $658 million, with U.S. sales down 10%[154] - U.S. revenues for Eliquis decreased 44% in Q1 2025, primarily due to generic erosion and lower average net selling prices[174] - U.S. revenues for Revlimid decreased 10% in Q1 2025, mainly due to lower average net selling prices[174] - U.S. revenues for Camzyos increased 63% in Q1 2025, primarily due to higher demand[164] - U.S. revenues for Krazati increased 116% in Q1 2025, driven by higher demand[166] - U.S. revenues for Cobenfy increased 133% in Q1 2025, attributed to expanded manufacturing capacity and new indication launches[167] Cost Management and Expenses - The company expects to achieve annual cost savings of approximately $2.0 billion by the end of 2027 through its productivity initiative[132] - Total expenses decreased by 65% in Q1 2025, from $23.4 billion in 2024 to $8.2 billion[182] - Research and development expenses decreased by 16% in Q1 2025, totaling $2.3 billion[182] - Selling, general and administrative expenses decreased by 33% in Q1 2025, totaling $1.6 billion[182] - Acquired IPRD charges totaled $188 million in Q1 2025, a decrease from $12,949 million in Q1 2024[186] - Amortization of acquired intangible assets decreased by $1.5 billion in Q1 2025, primarily due to the full amortization of Revlimid[187] Regulatory Approvals and Product Launches - Significant regulatory approvals in Q1 2025 included Opdivo + Yervoy for advanced hepatocellular carcinoma and colorectal cancer in the U.S. and EU[131][141] - The launch of Opdivo Qvantig in January 2025 is expected to enhance the company's oncology portfolio[157] - Augtyro received EC approval for treating ROS1-positive advanced NSCLC and advanced solid tumors expressing NTRK gene fusion in February 2025[205] - Breyanzi was approved by the EC for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in March 2025, based on the Phase II TRANSCEND FL study[205] - Camzyos received manufacturing and marketing approval in Japan for treating adults with oHCM in March 2025, based on results from the global Phase III EXPLORER-HCM study[205] - Opdivo Qvantig injection was recommended for approval by the CHMP for subcutaneous use in March 2025, demonstrating noninferiority in co-primary endpoints compared to its intravenous formulation[206] - Opdivo + Yervoy was approved by the FDA as a first-line treatment for unresectable or metastatic HCC in April 2025, based on the Phase III CheckMate-9DW trial results[206] Tax and Net Income - The effective tax rate for Q1 2025 was 17.1%, significantly improved from (3.4)% in Q1 2024, influenced by a $12.1 billion one-time charge in 2024[190] - Non-GAAP net earnings for Q1 2025 were $3,668 million, compared to a loss of $8,910 million in Q1 2024[196] - Other (income)/expense, net increased by $258 million, resulting in a net income of $339 million in Q1 2025 compared to $81 million in Q1 2024[188] Cash Flow and Debt Management - The net debt position improved by $886 million to $(37,584) million as of March 31, 2025, driven by $2.0 billion cash provided by operations[197] - Cash flow from operating activities was $1,954 million in Q1 2025, down $880 million from $2,834 million in Q1 2024[201] - Cash used in investing activities was $(499) million in Q1 2025, a significant decrease from $(19,618) million in Q1 2024 due to lower acquisition-related payments[203] - Dividend payments amounted to $1.3 billion during Q1 2025, reflecting the company's ongoing commitment to returning value to shareholders[200] - The company had no borrowings outstanding under any revolving credit facility as of March 31, 2025, indicating strong liquidity management[199] Clinical Trial Results - Sotyktu showed positive data in the Phase III POETYK PsA-2 trial, achieving ACR20 response in 54.2% of treated patients compared to 39.4% in placebo after 16 weeks[206] - The Phase III ODYSSEY-HCM trial for Camzyos did not meet its dual primary endpoints in April 2025, leading to updates in the U.S. Prescribing Information[205] - The Phase III RELATIVITY-098 trial for Opdualag did not meet its primary endpoint of recurrence-free survival in February 2025[206] Accounting Policies - The company reported no material changes to critical accounting policies during the three months ended March 31, 2025[207]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Revenues came to $11.2bn, down 6% year-on-year on a constant currency basis. Non-GAAP earnings per share ("EPS") came to $1.80, and GAAP EPS $1.20, compared to $(4.40) and ...

Bristol Myers Squibb (BMY) reported $11.2 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 5.6%. EPS of $1.80 for the same period compares to -$4.40 a year ago.The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $10.73 billion. With the consensus EPS estimate being $1.51, the EPS surprise was +19.21%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Q1 2025 Results April 24, 2025 Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are ...